Enzon biotech sale under threat
The possible sell-off of Enzon Pharmaceuticals’ biotechnology drugs business has come under fire by one of the firm’s shareholders, DellaCamera Capital Management, which says it is opposed to the move.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs